top of page
![77dc1c_6b758fca2d9d96213da64d719c37e298.](https://static.wixstatic.com/media/7a7e40_67bded8d7e3f464a8fd7cbfcb1646469~mv2.png/v1/fill/w_992,h_246,al_c,lg_1,q_85,enc_auto/77dc1c_6b758fca2d9d96213da64d719c37e298_.png)
![REPRIEVE.png](https://static.wixstatic.com/media/7a7e40_324c14f25df44b5b87b24c91afa0f146~mv2.png/v1/fill/w_212,h_54,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/REPRIEVE.png)
REPRIEVE EU - Randomized Trial to Prevent Vascular Events in HIV
A phase III study evaluating the effect of Pitavastatin to prevent cardiovascular events in HIV-1 infected individuals
NEAT ID EU5332
EUDRACTNumber: 2018-001285-41
CO-SPONSORS:
NEAT ID Foundation & Massachusetts General Hospital
Indication: HIV-infected patients on ART considered at low to moderate risk for cardiovascular disease and without a history of cardiovascular disease
Countries: Spain
Sites: 13
Status: Closed to Recruitment
bottom of page